CorMedix Inc. (CRMD)
NASDAQ: CRMD
· Real-Time Price · USD
9.64
0.45 (4.90%)
At close: May 01, 2025, 3:59 PM
9.50
-1.49%
After-hours: May 01, 2025, 06:27 PM EDT
Company Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.
The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CorMedix Inc.
| Country | United States |
| IPO Date | May 13, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Joseph Todisco MBA |
Contact Details
Address: 300 Connell Drive Berkeley Heights, New Jersey United States | |
| Website | https://www.cormedix.com |
Stock Details
| Ticker Symbol | CRMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410098 |
| CUSIP Number | 21900C308 |
| ISIN Number | US21900C3088 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph Todisco MBA | Chief Executive Officer & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 08, 2025 | 8-K | Current Report |
| Apr 04, 2025 | SCHEDULE 13G | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |